40% off all research productsUse codeSOFTLAUNCHApply & shop →
NVO Health
Research cart Log In
FDA approved Healthy Aging

Abaloparatide

Also called Tymlos

An FDA-approved prescription bone-building medicine for osteoporosis in adults at high fracture risk. It is not a general recovery supplement, and a research vial is not the approved pen.

Overview

What it is

A synthetic analogue of parathyroid hormone-related peptide (PTHrP) that activates the PTH1 receptor.

How it works

Activating the PTH1 receptor in a controlled, intermittent way stimulates new bone formation, rather than mainly slowing bone loss.

What the research shows

In ACTIVE, daily abaloparatide reduced new spine fractures versus placebo in postmenopausal women and improved bone density; high blood calcium occurred in 3.4% versus 6.4% with teriparatide. In ATOM, men gained about 8.5% spine bone density at 12 months versus 1.2% on placebo. In ACTIVExtend, women who switched to alendronate after abaloparatide had 0.9% new spine fractures over 43 months versus 5.6% in the placebo-then-alendronate group.

Studied for

  • Postmenopausal osteoporosis at high fracture riskapproved
  • Osteoporosis in menapproved, bone density

Safety and regulatory status

Safety and side effects

Possible side effects include dizziness, nausea, headache, tiredness, injection-site discomfort and lightheadedness on standing. Screening matters for high calcium, kidney stones and bone-cancer risk factors. It caused bone cancer in rats; whether it does in humans is unknown. The 2026 label also addresses severe allergic reactions. Lifetime use beyond two years is not recommended.

Regulatory status

FDA approved by prescription (Tymlos) for specific osteoporosis indications.

Mixing and dosing reference

Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.

Abaloparatide (3 mg Vial) Dosage Protocol

Vial
3 mg Abaloparatide
Add diluent
3 mL
Concentration
1 mg/mL
1 unit (U-100)
10 mcg in 0.01 mL
Route
Subcutaneous

One-Vial Calculation Using the Human-Study Daily Amount

Research PeriodAmount per AdministrationU-100 Units (mL)
37 daily administrations (one-vial arithmetic)80 mcg8 units (0.08 mL)

How to mix

  1. Clean the vial stopper and diluent stopper with alcohol; allow both to dry.
  2. Draw exactly 3.0 mL of bacteriostatic water with a new sterile syringe, then inject it slowly down the inside wall of the vial.
  3. Gently swirl or roll until dissolved. Do not shake.
  4. Label the vial with compound, concentration, and preparation date. Store it according to verified product-specific instructions.

Protocol source: PeptideDosages.com

Common questions

Is abaloparatide the same as teriparatide?

No. Both build bone through the PTH1 pathway, but they are different molecules with different side-effect findings.

Will I feel it working?

Probably not. Progress is tracked with bone-density scans and fracture history.

What happens after treatment ends?

Guidelines recommend following with a bone-preserving medicine to keep the gains. Plan this with your prescriber.

Related in Healthy Aging

BronchogenLab / animal only CardiogenLab / animal only ChonlutenEarly human data Epithalon (Epitalon)Early human data FOXO4-DRILab / animal only HGH 191AA (Somatropin)FDA approved
Sources and further reading (6)
  1. DailyMed. Tymlos prescribing information, rev. Aug 2026.
  2. Miller PD, et al. Abaloparatide vs placebo on new vertebral fractures (ACTIVE). JAMA, 2016.
  3. Czerwinski E, et al. Abaloparatide in men with osteoporosis (ATOM). J Bone Miner Res, 2022.
  4. Bone HG, et al. ACTIVExtend. J Clin Endocrinol Metab, 2018.
  5. MedlinePlus. Abaloparatide injection patient information.
  6. Source summary: PeptideDosages.com research overview (rewritten for NVO).
Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.